Induction of systemic anti-melanoma immunity through intratumoral TLR-7/8 activation
2014
Purpose Intratumoral immune activation can induce systemic immunity and anti-tumor activity. Imiquimod is a creamformulated, TLR-7 agonist that is FDA-approved for the treatment of non-melanoma skin cancers, but has limited activity against melanoma. In the current study, we studied the anti-tumor activity and mechanism of action of a novel injectable TLR 7/8 dual agonist, 3M-052, which remains at the site of injection to avoid systemic distribution.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI